Abstract
Lumiracoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) approved for the relief of symptoms of chronic inflammatory conditions. The aim of this study was to evaluate the effects of this specific inhibitor of COX-2 as adjunctive treatment on induced periodontitis in rats. Periodontal disease was induced at the first mandibular molar of 60 rats. After 7 days, the ligature was removed and all animals were submitted to scaling and root planing (SRP) along with local irrigation with saline solution and were divided into 2 groups: SRP (n = 30)—received subcutaneous injections of 1 mg/kg of body weight/day of saline solution for 3 days and; SRP + L (n = 30)—received subcutaneous injections of 1 mg/kg of body weight/day of Lumiracoxib for 3 days. Ten animals in each group were killed at 7, 15, and 30 days. The histological description was performed and the histometric values were statistically analyzed. In Group SRP + L, the histometric analysis (0.58 ± 0.08, 0.64 ± 0.06, and 0.56 ± 0.10 mm2) showed less bone loss (p < 0.05) than Group SRP (1.52 ± 0.08, 1.55 ± 0.09, and 1.49 ± 0.24 mm2) at 7, 15, and 30 days, respectively. Within the limits of this study it can be concluded that subcutaneous application of specific inhibitor of COX-2 was a beneficial adjunctive treatment for periodontal diseases induced in rats.
Similar content being viewed by others
References
Azoubel MC, Menezes AM, Bezerra D et al (2007) Comparison of etoricoxib and indomethacin for the treatment of experimental periodontitis in rats. Braz J Med Biol Res 40:117–125
Azoubel MC, Sarmento VA, Cangussú V (2008) Adjunctive benefits of etoricoxib in non-surgical treatment of aggressive periodontitis—short-term evaluation. J Periodontol 79:1719–1725
Bezerra MM, de Lima V, Alencar VB (2000) Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats. J Periodontol 71:1009–1014
Bissada NF, Ng VW (1998) Clinical evaluation of systemic doxycycline and ibuprofen administration as an adjunctive treatment for adult periodontitis. J Periodontol 69:772–776
Cavagni J, Soletti AC, Gaio EG et al (2005) The effect of dexamethasone in the pathogenesis of ligature-induced periodontal disease in Wistar rats. Braz Oral Res 19:290–294
Chandrasekharan NV, Dai H, Roos KL (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99:13926–13931
Crotti T, Smith MD, Hirsch R et al (2003) Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 38:380–387
De Almeida JM, Theodoro LH, Bosco AF et al (2008) Treatment of experimental periodontal disease by photodynamic therapy in rats with diabetes. J Periodontol 79:2156–2165
Engelhardt G (1996) Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol 35:4–12
Fleischmann R, Sheldon E, Maldonado-Cocco J et al (2006) Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. Clin Rheumatol 25:42–53
Furlaneto FA, Nagata MJ, Fucini SE et al (2007) Bone healing in critical-size defects treated with bioactive glass/calcium sulfate: a histologic and histometric study in rat calvaria. Clin Oral Implants Res 18:311–318
Haffajee AD, Cugini MA, Dibart S et al (1997) The effect of SRP on the clinical and microbiological parameters of periodontal diseases. J Clin Periodontol 24:324–334
Hilário MOE, Terreri MT, Len CA (2006) Nonsteroidal anti-inflammatories, COX 2 inhibitors, indications, adverse effects. J Pediatric 82:206–212
Hofbauer LC, Lacey DL, Dunstan CR et al (1999) Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25:255–259
Holanda Pinto SA, Pinto LM, Cunha GM et al (2008) Anti-inflammatory effect of alpha, beta-amyrin, a pentacyclic triterpene from Protium heptaphyllum in rat model of acute periodontitis. Inflammopharmacology 16:48–52
Holzhausen M, Rossa C Jr, Marcantonio E Jr et al (2002) Effect of selective cyclooxygenase-2 inhibition on the development of ligature-induced periodontitis in rats. J Periodontol 73:1030–1036
Li KL, Vogel R, Jeffcoat MK (1996) The effect of ketoprofen creams on periodontal disease in rhesus monkeys. J Periodontol Res 31:525–532
Liu D, Xu JK, Figliomeni L et al (2003) Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. Int J Mol Med 11:17–21
Lohinai Z, Stachlewitz R, Szekely AD et al (2001) Evidence for the expression of cyclooxygenase-2 enzyme in periodontitis. Life Sci 70:279–290
Mangold JB, Gu H, Rodriguez LC et al (2004) Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 32:566–571
Meisel P, Kocher T (2005) Photodynamic therapy for periodontal diseases: state of the art. J Photochem Photobiol B 79:159–170
Mitchell JA, Larkin S, Williams TJ (1995) Cyclooxygenase 2: regulation and relevance in inflammation. Biochem Pharmacol 5:1535–1542
Miyauchi M, Hiraoka M, Oka H (2004) Immuno- localization of COX-1 and COX-2 in the rat molar periodontal tissue after topical application of lipopolysaccharide. Arch Oral Biol 49:739–746
Morton RS, Dongari-Bagtzoglou AI (2001) Cyclooxygenase-2 is upregulated in inflamed gingival tissues. J Periodontol 72:461–469
Mousques T, Listgarten M, Phillips R (1980) Effect of scaling and root planning on the composition of the human subgingival microbial flora. J Periodontal Res 15:144–151
Nogueira-Filho GR, Rosa BT, César-Neto JB et al (2007) Low- and high-yield cigarette smoke inhalation potentiates bone loss during ligature-induced periodontitis. J Periodontol 78:730–735
Nyman S, Schroeder HE, Lindhe J (1979) Suppression of Inflammation and bone resorption by indomethacin during experimental periodontitis in dogs. J Periodontol 50:450–461
Offenbacher S, Heasman PA, Collins JG (1993) Modulation of host PGE2 secretion as a determinant of periodontal disease expression. J Periodontol 64:432–444
Oliveira TM, Sakai VT, Machado MA (2008) COX-2 inhibition decreases VEGF expression and alveolar bone loss during the progression of experimental periodontitis in rats. J Periodontol 79:1062–1069
Page RC (2002) The etiology and pathogenesis of periodontitis. Compend Contin Educ Dent 23:11–14
Paquette DW, Williams RC (2000) Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases. Periodontology 24:239–252
Petersilka GJ, Ehmke B, Flemming TF (2002) Antimicrobial effects of mechanical debridement. Periodontol 2000 28:56–71
Rordorf CM, Choi L, Marshall P et al (2005) Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 44:247–1266
Sato Y, Arai N, Negishi A et al (1997) Expression of cyclooxygenase genes and involvement of endogenous prostaglandin during osteogenesis in the rat tibial bone marrow cavity. J Med Dent Sci 44:81–92
Taiyeb Ali TB, Waite IM (1993) The effect of systemic ibuprofen on gingival inflammation in humans. J Clin Periodontol 20:723–728
Umeda M, Takeuchi Y, Noguchi K et al (2004) Effects of non-surgical periodontal therapy on the microbiota. Periodontol 2000 36:98–120
Weaks-Dybvig M, Sanavi F, Zander H et al (1982) The effect of indomethacin on alveolar bone loss in experimental periodontitis. J Periodontol Res 17:90–100
Williams RC, Paquette DW (2000) Understanding the pathogenesis of periodontitis: a century of discovery. J Int Acad Periodontol 2:59–63
Williams R, Jeffcoat MK, Howell TH (1988) Ibuprofen: an inhibitor of treatment of alveolar bone resorption in beagles. J Periodontol Res 23:225–229
Ximenez-Fyvie LA, Haffajee AD, Socransky SS (2000) Microbial composition of supra- and subgingival plaque in subjects with adult periodontitis. J Clin Periodontol 27:722–732
Yen CA, Damoulis PD, Stark PC et al (2008) The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis. J Periodontol 79:104–113
Zhang X, Schqarz EM, Young DA et al (2002) Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 110:1211
Zubery Y, Dunstan CR, Story BM (1998) Bone resorption caused by three periodontal pathogens in vivo in mice is mediated in part by prostaglandin. Infect Immun 66:4158–4162
Acknowledgments
We thank to the Foundation of Support the Research of the State of São Paulo (Fapesp) for the financial support for the accomplishment of this research (Fapesp process 06/06358-0). This work is attributed to the Department of Periodontology, Araçatuba Dental School, State University of São Paulo (UNESP) Araçatuba, São Paulo, Brazil. The authors would also like to thank Bruno Theodoro Luciano, from the Institute of International Relations from the University of Brasília, for the English review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Garcia, V.G., Takano, R.Y., Fernandes, L.A. et al. Treatment of experimental periodontal disease by a selective inhibitor of cyclooxygenase-2 with scaling and root planing (SRP). Inflammopharmacol 18, 293–301 (2010). https://doi.org/10.1007/s10787-010-0059-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-010-0059-z